Viking Therapeutics Gestione
Gestione criteri di controllo 2/4
Viking Therapeutics Il CEO è Brian Lian, nominato in Sep2012, e ha un mandato di 12.17 anni. la retribuzione annua totale è $ 12.63M, composta da 4.9% di stipendio e 95.1% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 1.71% delle azioni della società, per un valore di $ 100.41M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 5.3 anni e 10.5 anni.
Informazioni chiave
Brian Lian
Amministratore delegato
US$12.6m
Compenso totale
| Percentuale dello stipendio del CEO | 4.9% |
| Mandato del CEO | 12.2yrs |
| Proprietà del CEO | 1.7% |
| Durata media del management | 5.3yrs |
| Durata media del Consiglio di amministrazione | 10.5yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Viking Therapeutics: Too Much Excitement Around Oral VK2735, Even If It Met High Expectations
Nov 04Viking Therapeutics: Lots Of Positives
Oct 28Viking Therapeutics: Market Rightly Excited By GLP-1 Promise -- A Buy Ahead Of Data
Sep 25Companies Like Viking Therapeutics (NASDAQ:VKTX) Can Afford To Invest In Growth
Sep 07
Viking Therapeutics: GLP-1/GIP Receptor Agonist And Its Competitive Landscape
Aug 30Viking Therapeutics: Better-Than-Expected Trial Timelines While Pipeline Expands
Jul 25We Think Viking Therapeutics (NASDAQ:VKTX) Can Easily Afford To Drive Business Growth
Apr 26Viking Therapeutics: Future Weight Loss Heavyweight?
Apr 02We're Hopeful That Viking Therapeutics (NASDAQ:VKTX) Will Use Its Cash Wisely
Jan 09We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate
Sep 21Viking Therapeutics (NASDAQ:VKTX) Is In A Good Position To Deliver On Growth Plans
Jun 07We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate
Mar 05Viking Therapeutics: Playing Second Fiddle To Madrigal
Aug 30We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth
Jul 13Revisiting Viking Therapeutics
Apr 20We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth
Apr 12We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth
Dec 17Viking Therapeutics: Remaining Bullish And Sticking To My Plan
Aug 27Viking Therapeutics soars 11% on encouraging VK0214 data in rare metabolic disorder
Jun 17Have Insiders Been Selling Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares This Year?
Jan 13Viking Therapeutics announces senior management appointments
Jan 06Do Institutions Own Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares?
Dec 09
Viking Therapeutics: Progressing Steadily, But Concerns Remain
Nov 29Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$99m |
| Jun 30 2024 | n/a | n/a | -US$97m |
| Mar 31 2024 | n/a | n/a | -US$94m |
| Dec 31 2023 | US$13m | US$615k | -US$86m |
| Sep 30 2023 | n/a | n/a | -US$81m |
| Jun 30 2023 | n/a | n/a | -US$74m |
| Mar 31 2023 | n/a | n/a | -US$72m |
| Dec 31 2022 | US$5m | US$612k | -US$69m |
| Sep 30 2022 | n/a | n/a | -US$62m |
| Jun 30 2022 | n/a | n/a | -US$59m |
| Mar 31 2022 | n/a | n/a | -US$57m |
| Dec 31 2021 | US$4m | US$594k | -US$55m |
| Sep 30 2021 | n/a | n/a | -US$54m |
| Jun 30 2021 | n/a | n/a | -US$50m |
| Mar 31 2021 | n/a | n/a | -US$44m |
| Dec 31 2020 | US$5m | US$577k | -US$39m |
| Sep 30 2020 | n/a | n/a | -US$36m |
| Jun 30 2020 | n/a | n/a | -US$32m |
| Mar 31 2020 | n/a | n/a | -US$31m |
| Dec 31 2019 | US$4m | US$525k | -US$26m |
| Sep 30 2019 | n/a | n/a | -US$24m |
| Jun 30 2019 | n/a | n/a | -US$24m |
| Mar 31 2019 | n/a | n/a | -US$23m |
| Dec 31 2018 | US$1m | US$485k | -US$22m |
| Sep 30 2018 | n/a | n/a | -US$21m |
| Jun 30 2018 | n/a | n/a | -US$20m |
| Mar 31 2018 | n/a | n/a | -US$19m |
| Dec 31 2017 | US$805k | US$440k | -US$21m |
Compensazione vs Mercato: La retribuzione totale di Brian ($USD 12.63M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 7.74M ).
Compensazione vs guadagni: La retribuzione di Brian è aumentata nonostante l'azienda non sia redditizia.
AMMINISTRATORE DELEGATO
Brian Lian (58 yo)
12.2yrs
Mandato
US$12,628,061
Compensazione
Dr. Brian Lian, Ph D., served as Director at Apricus Biosciences, Inc. He has been the Chief Executive Officer and President at Viking Therapeutics, Inc. since September 24, 2012. Dr. Lian has been an Inde...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 12.2yrs | US$12.63m | 1.71% $ 100.4m | |
| Chief Financial Officer | 5.3yrs | US$3.50m | 0.0010% $ 60.4k | |
| Chief Operating Officer | 3.8yrs | US$3.51m | 0.18% $ 10.8m | |
| Vice President of Finance & Administration | 6.6yrs | US$619.56k | Nessun dato | |
| Senior Vice President of Pharmaceutical Development | 1.8yrs | Nessun dato | Nessun dato |
5.3yrs
Durata media
58.5yo
Età media
Gestione esperta: Il team dirigenziale di VKTX è esperto e expertise (durata media dell'incarico 5.3 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 12.2yrs | US$12.63m | 1.71% $ 100.4m | |
| Scientific Advisor | no data | Nessun dato | Nessun dato | |
| Independent Director | 10.5yrs | US$169.37k | 0.10% $ 5.9m | |
| Independent Director | 10.5yrs | US$192.77k | 0.0085% $ 499.9k | |
| Independent Director | 7.3yrs | US$189.62k | 0.027% $ 1.6m | |
| Scientific Advisor | no data | Nessun dato | Nessun dato | |
| Scientific Advisor | no data | Nessun dato | Nessun dato | |
| Scientific Advisor | no data | Nessun dato | Nessun dato | |
| Scientific Advisor | no data | Nessun dato | Nessun dato | |
| Independent Chairman | 10.5yrs | US$222.72k | 0.043% $ 2.5m | |
| Scientific Advisor | no data | Nessun dato | Nessun dato | |
| Independent Director | 5.3yrs | US$178.65k | 0% $ 0 |
10.5yrs
Durata media
63.5yo
Età media
Consiglio di amministrazione esperto: Il consiglio di amministrazione di VKTX è composto da personale esperto e esperto (durata media dell'incarico 10.5 anni).